With reference to the report published, the global deep brain stimulation devices market was prized by USD 1.12 billion in 2020. It is estimated to witness a 9.3% CAGR from 2021 to 2028.
Deep brain stimulation is the surgical procedure for inserting a piece of equipment that sends an indication to brain segments, accountable for the movement of a body. Deep brain stimulation assists in dropping the indications of walking troubles, sluggishness, as well as stiffness, sourced by a variety of neurological sicknesses like Parkinson’s sickness and dystonia. Normally, this treatment is suggested to those patients, who are unable to act in response to the medicines, for as a minimum as five years.
The rising figure of the patients, affected by uncontrolled activities connected with Parkinson’s sickness, dystonia, along with the several cases of sclerosis, is anticipated to impel the enlargement of the market for DBS devices. Additionally, rising demand for the minimally invasive method, because of the better patient result is, moreover, a seriously influencing propeller of the market.
This treatment is, moreover, accepted by the U.S. FDA for those patients who are unable to have epilepsy surgical procedures that detach or take out the portion of the brain, which sources the attack.
Accordingly, the increasing frequency of neurological circumstances, like Parkinson’s disease and Alzheimer’s are the most important reasons, compelling the expansion of the market. Rising occurrences of neurological sicknesses, like epilepsy, essential tremors, dystonia, Parkinson’s disease, are the extreme influence making drivers of the deep brain stimulation (DBS) devices market.
Besides, rising alertness regarding the vast neurological sicknesses has increased the demand for deep brain stimulators devices such as another treatment. This is anticipated to power the progress of the market for the duration of the forecast.
Additionally, the technical improvement in deep brain stimulation equipment is expected to generate expansion openings, within this market. This technical development consists of personalized directed programming, multi-target stimulation, robot-assisted implantation, rechargeable implantable pulse generators, and improved microelectrode designs.
In 2020, due to the rising number of endorsements from the U.S. FDA for deep brain stimulation treatment and the internationally greater occurrences of the sickness, the Parkinson's sickness division retained a 65.2% revenue share and dominated the DBS devices market.
On the other hand, the epilepsy sector is projected to observe a maximum of 16.2% CAGR, throughout the forecast period. Increasing knowledge regarding the sophisticated alternatives of the treatment for epilepsy, together with rising healthcare infrastructure, is anticipated to additionally power the expansion of the sector, during the near future.
The greater acceptance of it in the surgical measures has caused the dual-channel section to hold 57.2% revenue share and dominate the deep brain stimulation devices market, in 2020. Dual channels are the largely efficient and the safest devices, utilized in surgical actions.
Thus, the greater occurrences of immobilizing neurological ailment, the rising quantity of surgical actions for Parkinson's sickness, and the increasing figure of hospitals utilizing dual-channel DBS devices are compelling the progress of the section.
On the other hand, the single-channel deep brain stimulation device sector is anticipated to observe a maximum of 9.5% CAGR, during the forecast period. Healthcare experts trust that single-channel presents additional programming alternatives to the neurologists. This caused a better inclination for single-channel deep brain stimulation devices.
The hospitals held the major, 52.0% revenue share and led the deep brain stimulation devices market in 2020, within the end-use sector. Mainly, the enlargement of this sector can be credited to the rise in the quantity of deep brain stimulation surgical treatments, carried out in hospitals and rush in the occurrence of Parkinson’s sickness, essential tremor. Moreover, the accessibility of the technically superior deep brain stimulation devices, together with constructive compensation strategy, is anticipated to force the expansion of section throughout the forecast period.
Conversely, the Ambulatory Surgical Centers (ASC) segment is estimated to rise by the maximum 9.8% CAGR, all through the forecast period. This is attributable to the lesser charges of the actions in contrast to the hospitals, low down infectivity percentage as related with hospitals and neurology clinics, and suitable admittance for the patient care plus the abridged waiting period.
On account of an enhancement in FDA endorsement for the deep brain stimulation devices in clinical function, North America held a 51.9% share and dominated the global market, in 2020. For example, the U.S. FDA accepted Brio, a deep brain stimulation device, for the therapy of Parkinson’s sickness, in 2015.
Besides, the growing number of patients identified with Parkinson's sickness together with increasing government financial support as well as plan for increasing alertness, regarding the movement problems is anticipated to propel the demand for deep brain stimulation devices, within the region.
On the other hand, Asia Pacific is likely to direct the deep brain stimulation devices market, extensively, during the forecast period. This is credited to the increasing frequency of neurodegenerative complaints, together with un-fulfilled requirements for efficient and long-standing resolutions.
Growing knowledge regarding neurological ailment treatment opportunities as well as the enhancement in the clinical development structure of rising markets is anticipated to propel the market growth within the region. Furthermore, the existence of important development openings in emergent nations like India, China, and Japan, are expected to add to the expansion of the market.
The major companies are, gradually more, concentrating on the technical progressions, presentation of innovative products plus the additional policies like mergers & acquisitions to build up their grip in the market.
For example, Liva Nova with Micro Port Scientific got the endorsement of Rega TM pacemakers from the Chinese FDA, in September 2019. These pacemakers are having the smallest size in the Chinese market for cardiac rhythm administration. This endorsement will make stronger the company’s regional existence; along with increasing its marks in China.
• LivaNova PLC
• Aleva Neurotherapeutics S.A.
• Medtronic
• Neuropace Inc.
• Nexstim
• Boston Scientific Corporation
• Abbott (St. Jude Medical)
Report Attribute |
Details |
The market size value in 2021 |
USD 1.22 billion |
The revenue forecast in 2028 |
USD 2.3 billion |
Growth Rate |
CAGR of 9.3% from 2021 to 2028 |
The base year for estimation |
2020 |
Historical data |
2016 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Russia; Netherlands; Switzerland; Sweden; Ireland; Poland; Japan; China; India; Australia; South Korea; Indonesia; Thailand; Philippines; Malaysia; Singapore; Brazil; Mexico; Colombia; Argentina; Chile; Venezuela; South Africa; Saudi Arabia; UAE; Turkey; Iran |
Key companies profiled |
Abbott (St. Jude Medical); Medtronic; Boston Scientific Corporation; Aleva Neurotherapeutics S.A.; Nexstim; LivaNova PLC; Neuropace Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail of customized purchase options to meet your exact research needs. |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Million Insights has segmented the global Deep Brain Stimulation (DBS) devices market report on the basis of product, application, end-use, and region:
• Product Outlook (Revenue, USD Million, 2016 - 2028)
• Single Channel
• Dual Channel
• Application Outlook (Revenue, USD Million, 2016 - 2028)
• Pain Management
• Epilepsy
• Essential Tremor
• Obsessive-Compulsive Disorder (OCD)
• Depression
• Dystonia
• Parkinson’s Disease
• Others
• End-use Outlook (Revenue, USD Million, 2016 - 2028)
• Hospitals
• Neurology Clinics
• Ambulatory Surgical Centers
• Research Centers
• Regional Outlook (Revenue, USD Million, 2016 - 2028)
• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Netherlands
• Switzerland
• Sweden
• Ireland
• Poland
• The Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Indonesia
• Thailand
• Philippines
• Malaysia
• Singapore
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Chile
• Venezuela
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• UAE
• Turkey
• Iran
Research Support Specialist, USA